AB Science S.A (AB) | Financial Analysis & Statements
AB Science S.A. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
23.2M
Total Liabilities
46.9M
Shareholders Equity
-23.8M
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2024
AB Science S.A Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 1.1M | 970.0K | 958.0K | 1.6M | 1.6M |
| Cost of Goods Sold | -176.0K | 383.0K | 31.0K | 111.0K | 69.0K |
| Gross Profit | 1.2M | 587.0K | 927.0K | 1.5M | 1.5M |
| Gross Margin % | 116.4% | 60.5% | 96.8% | 93.1% | 95.6% |
| Operating Expenses | |||||
| Research & Development | 3.9M | 10.5M | 13.3M | 11.2M | 12.8M |
| Selling, General & Administrative | 1.9M | 1.8M | 2.2M | 2.7M | 3.4M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 5.9M | 12.3M | 15.5M | 14.0M | 16.3M |
| Operating Income | -6.1M | -13.4M | -15.9M | -13.8M | -14.7M |
| Operating Margin % | -567.4% | -1,384.4% | -1,663.7% | -859.2% | -931.7% |
| Non-Operating Items | |||||
| Interest Income | 0 | 2.7M | 1.1M | 887.0K | 63.0K |
| Interest Expense | 2.2M | 2.5M | 2.0M | 1.3M | 117.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -7.8M | -12.0M | -13.6M | -14.4M | -15.0M |
| Income Tax | - | 0 | 4.0K | 36.0K | 8.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -7.8M | -12.0M | -13.6M | -14.5M | -15.0M |
| Net Margin % | -730.5% | -1,235.6% | -1,421.2% | -900.0% | -950.4% |
| Key Metrics | |||||
| EBITDA | -5.1M | -7.4M | -11.6M | -11.4M | -13.8M |
| EPS (Basic) | €-0.15 | €-0.24 | €-0.29 | €-0.30 | €-0.34 |
| EPS (Diluted) | €-0.15 | €-0.24 | €-0.29 | €-0.30 | €-0.34 |
| Basic Shares Outstanding | 53274886 | 49664905 | 47139023 | 47520850 | 44225682 |
| Diluted Shares Outstanding | 53274886 | 49664905 | 47139023 | 47520850 | 44225682 |
Income Statement Trend
AB Science S.A Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 8.0M | 6.1M | 7.3M | 8.7M | 20.7M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 130.0K | 236.0K | 160.0K | 310.0K | 354.0K |
| Inventory | 184.0K | 336.0K | 456.0K | 141.0K | 79.0K |
| Other Current Assets | - | - | - | - | - |
| Total Current Assets | 14.5M | 19.4M | 20.9M | 18.2M | 26.3M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 256.0K | 254.0K | 1.2M | 1.5M | 2.4M |
| Goodwill | 1.3M | 1.4M | 1.6M | 1.4M | 1.5M |
| Intangible Assets | 1.3M | 1.4M | 1.6M | 1.4M | 1.5M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | 3.0K | 3.0K | 3.0K | 2.0K |
| Total Non-Current Assets | 8.7M | 6.1M | 3.0M | 3.1M | 3.4M |
| Total Assets | 23.2M | 25.5M | 23.8M | 21.3M | 29.7M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 6.0M | 6.5M | 7.4M | 6.3M | 13.3M |
| Short-term Debt | 3.9M | 2.1M | 4.7M | 629.0K | 4.7M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.9M | 303.0K | 841.0K | 43.0K | 33.0K |
| Total Current Liabilities | 20.4M | 18.7M | 23.1M | 17.5M | 22.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 14.5M | 17.0M | 19.3M | 7.7M | 2.3M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 11.1M | 9.9M | 11.8M | 11.5M | 10.2M |
| Total Non-Current Liabilities | 26.5M | 27.8M | 36.4M | 27.0M | 26.6M |
| Total Liabilities | 46.9M | 46.5M | 59.5M | 44.5M | 49.2M |
| Equity | |||||
| Common Stock | 579.0K | 511.0K | 469.0K | 469.0K | 459.0K |
| Retained Earnings | - | - | - | - | - |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -23.8M | -21.0M | -35.7M | -23.2M | -19.5M |
| Key Metrics | |||||
| Total Debt | 18.5M | 19.1M | 24.0M | 8.4M | 7.1M |
| Working Capital | -5.9M | 707.0K | -2.2M | 705.0K | 3.7M |
Balance Sheet Composition
AB Science S.A Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -7.8M | -12.0M | -13.6M | -14.5M | -15.0M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 1.0M | 605.0K | 133.0K | 258.0K | 95.0K |
| Working Capital Changes | 0 | 0 | 0 | 0 | 0 |
| Operating Cash Flow | -6.2M | -14.7M | -14.6M | -13.4M | -14.8M |
| Investing Activities | |||||
| Capital Expenditures | -136.0K | -345.0K | -644.0K | -564.0K | -370.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | 0 | 0 | 0 | 0 | 0 |
| Investment Sales | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | -136.0K | -345.0K | -644.0K | -564.0K | -370.0K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 6.0M | 16.6M | 6.0M | 6.1M |
| Debt Repayment | -2.4M | -1.2M | -188.0K | -4.3M | -6.0K |
| Financing Cash Flow | -2.4M | 4.8M | 16.4M | 1.7M | 6.1M |
| Free Cash Flow | 370.0K | -17.2M | -18.1M | -17.7M | -13.9M |
| Net Change in Cash | -8.7M | -10.3M | 1.2M | -12.3M | -9.2M |
Cash Flow Trend
AB Science S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-7.73
Forward P/E
-8.24
Price to Sales
74.37
PEG Ratio
-8.24
Profitability Ratios
Profit Margin
116.42%
Operating Margin
-529.71%
Return on Equity
32.97%
Return on Assets
-14.79%
Financial Health
Current Ratio
0.67
Debt to Equity
-0.80
Beta
1.29
Per Share Data
EPS (TTM)
€-0.15
Book Value per Share
€-0.41
Revenue per Share
€0.02
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| AB | 76.8M | -7.73 | - | 32.97% | 116.42% | -0.80 |
| Ipsen S.A | 13.4B | 30.83 | 3.12 | 10.44% | 11.29% | 22.38 |
| Euroapi S.A.S.U | 121.5M | 8.84 | 0.20 | -23.84% | -24.77% | 8.30 |
| CoreTech Limited | 1.3M | - | - | -102.42% | 137.36% | -1.03 |
| Boiron S.A | 446.2M | 23.15 | 1.21 | 5.22% | 3.84% | 4.90 |
Financial data is updated regularly. All figures are in the company's reporting currency.